Related Experiment Video
Updated: Dec 31, 2025
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Immunological Complexity of the Prostate Cancer Microenvironment Influences the Response to Immunotherapy
Nataliya Prokhnevska1, Dana A Emerson2,3, Haydn T Kissick4
1Department of Urology, Emory University, Atlanta, GA, USA.
Abstract:
Prostate cancer is one of the most common cancers in men and a leading cause of cancer-related death. Recent advances in the treatment of advanced prostate cancer, including the use of more potent and selective inhibitors of the androgen signaling pathway, have provided significant clinical benefit for men with metastatic castration-resistant prostate cancer (mCRPC). However, most patients develop progressive lethal disease, highlighting the need for more effective treatments. One such approach is immunotherapy, which harness the power of the patient's immune system to identify and destroy cancer cells through the activation of cytotoxic CD8 T cells specific for tumor antigens. Although immunotherapy, particularly checkpoint blockade, can induce significant clinical responses in patients with solid tumors or hematological malignancies, minimal efficacy has been observed in men with mCRPC. In the current review, we discuss our current understanding of the immunological complexity of the immunosuppressive prostate cancer microenvironment, preclinical models of prostate cancer, and recent advances in immunotherapy clinical trials to improve outcomes for men with mCRPC.
Insights
Advanced prostate cancer treatments show promise, but most patients progress. Immunotherapy offers a new approach by activating the immune system, but its effectiveness in metastatic castration-resistant prostate cancer (mCRPC) needs further research.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- Prostate cancer is a leading cause of cancer death in men.
- Advanced treatments like androgen signaling inhibitors benefit metastatic castration-resistant prostate cancer (mCRPC) patients.
- Treatment resistance necessitates novel therapeutic strategies.
Purpose of the Study:
- To review the immunological complexity of the prostate cancer microenvironment.
- To discuss preclinical models for studying prostate cancer.
- To summarize recent immunotherapy clinical trials for mCRPC.
Main Methods:
- Review of current literature on prostate cancer immunology.
- Analysis of preclinical models of prostate cancer.
- Examination of clinical trial data for immunotherapies in mCRPC.
Main Results:
- The prostate cancer microenvironment is complex and immunosuppressive.
- Immunotherapy, including checkpoint blockade, shows limited efficacy in mCRPC.
- Understanding the tumor microenvironment is crucial for improving immunotherapy response.
Conclusions:
- Despite advances, progressive lethal disease remains a challenge in advanced prostate cancer.
- Immunotherapy holds potential but faces significant hurdles in mCRPC.
- Further research into the tumor microenvironment and novel immunotherapy strategies is essential for improving patient outcomes.
Related Concept Videos
02:17The Tumor Microenvironment
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...